drugset

drugset / Trial / NCT05997017

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

NCT05997017 ↗

Phase 2 Recruiting 29 enrolled Aadi Bioscience, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Timeline

Start: 2023-12-28
Primary completion: 2026-12
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	nab-sirolimus	Unknown	—	Intravenous

Indications